Partnerships Archives

News and Trends 14 Dec 2022

PrecisionLife to work on R&D with Ono Pharmaceutical

PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PhoreMost and ThinkCyte collaborate on AI-based drug discovery

PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 13 Dec 2022

Therabest and Glycotope to assess breast cancer combination treatment

Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNK (enhanced iPSC-derived NK) cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer (TNBC) patients. NK (natural killer) cell therapies from various cell sources have demonstrated exciting results in early clinical trials […]

December 13, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]

December 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Metrion and KCNC1 Foundation announce collaboration to identify therapeutic

Metrion Biosciences Limited, and The KCNC1 Foundation are to collaborate to try and find a therapeutic for children. The KCNC1 Foundation is a not-for-profit organization focused on the development of a treatment for an ultra-rare genetic disorder. Variants of the KCNC1 gene impact Kv3.1 potassium channel function, resulting in neurodevelopmental disorders, which can include progressive […]

December 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Dec 2022

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […]

December 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Dec 2022

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Tris Pharma, Inc announced today (December 2) that they have expanded their partnership allowing Pediatrix Therapeutics to receive exclusive rights to commercialize its entire FDA-approved ADHD portfolio as well as ADHD pipeline products in China. Tris says it has a robust portfolio of FDA-approached products for the treatment of attention deficit/hyperactivity disorder (ADHD) and a pipeline of treatments […]

December 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

Mycotechnology and IFF join forces in Europe to create better food system

Mycotechnology, a company using mycelia, the roots of mushrooms, and IFF have formed a partnership to co-develop alternative proteins. The two companies have already partnered in the U.S. and the new collaboration in Europe, they say, reflects their shared commitment of bringing a better food system and ‘next-generation’ food and drink products to the European […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

November 28, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us